   
 
 
 
 
 
Study Title:  Evaluation of 3M Clear Aligner for Correction of Class I, II and III 
Malocclusion Study  
 
Study ID: [REMOVED]  
 
Document Date:  19 April 2017  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005  
   
 
Health Care 
3M Center  
St. Paul, MN 55144 -1000  Page 1  of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM 
 
 
 
 
 
 
 
Clinical Study Protocol  
 
 
Based on the International Conference on Harmonisation 
E6Good Clinical Practice  
Consolidated Guideline 
Federal Register: Docket No.  95D-0219  
62 FR 25692/May 9, 1997  
 
 
Study Sponsor: 3M Healthcare 
Study Funded By: 3M Healthcare  

Page 2 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
 
 
Study Number: 
Study Title:  
 
Principal Investigators: 
Rese arch Facilities:  Clinical Study Protocol  
CLIN -INDEX -US-05-013821/11 -050005  
Evaluation of 3M Clear Aligner for Correction of Class I, II and III 
Malocclusion Study  
Multi – Site Investigators 
Multi Center  
IRB Western Institutional Review Board  (WIRB)  
1019 39th Avenue SE Suite 120  
Puyallup, WA 98374 -2115  
 
Sponsor  3M Health  Care  
Oral Care Division  
3M Center Building 270 -4N-01 
St. Paul, MN 55144 -1000  
 
3M Study Monitor:  
 
 
 
 
 
 
3M Medical Monitor:  Gail E. Maxey 
3M Health Care  
3M Center Building 270 -4N-01 
St. Paul, MN  55144 -1000  
Telephone:  651-575-4325  
FAX: 651 -736-1518  
Email: gemaxey@mmm.com  
 
Andreas Syrek, Dr. MD., 
D.D.S.: PhD  
3M Oral Care  
 
Approver List (3M Approvers Only):  
Signer  Role  Date Signed  
US264596:Klinger Nancy M  Clinical  April 19, 2017 09:53:30 AM  
   
   
 
3M Confidential  
This document contains confidential information that is the property of 3M and is subject 
to all of the restrictions on use and disclosure contained in the study contract to which this 
is appended. Do not copy, disclose, circulate or use for benefit for any third party without 
written authorization from 3M.  
Page 3 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
Page 4 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
Table of Contents  
1. BACKGROUND  INFORMATION  ................................ ................................ ................................ ................................ ... 6 
1.1 NAME, DESCRIPTION AND INTENDED USE OF THE PRODUCT  FOR  INVESTIGATION  ...................... 6 
1.2 RISK/BENEFIT  SUMMARY  ................................ ................................ ................................ ................................ ........... 6 
1.2.1 Risks  6 
1.2.2 Benefits  ................................ ................................ ................................ ................................ .. 7 
1.3 MATERIAL  APPLICATION  ................................ ................................ ................................ ................................ ............ 7 
1.4 GOOD CLINICAL PRACTICE (GCP) AND  REGULATORY  REQUIREMENTS  ................................ ....... 8 
1.5 STUDY  POPULATION  ................................ ................................ ................................ ................................ ...................... 8 
2. STUDY PURPOSE  AND  OBJECTIVES  ................................ ................................ ................................ ....................  8 
2.1 PRIMARY  OBJECTIVE  ................................ ................................ ................................ ................................ ............  8 
2.2 SECONDARY  OBJECTIVES  ................................ ................................ ................................ ................................ .... 8 
3. STUDY  DESIGN  ................................ ................................ ................................ ................................ ............................  9 
3.1 STUDY  TYPE  ................................ ................................ ................................ ................................ ..............................  9 
3.2 PRIMARY AND  SECONDARY  ENDPOINTS  ................................ ................................ ................................ ........  9 
3.2.1 Primary  Endpoint  ................................ ................................ ................................ ...................  9 
3.2.2 Secondary  Endpoints  ................................ ................................ ................................ ..............  9 
3.3 RANDOMIZATION  AND  BLINDING  ................................ ................................ ................................ .....................  9 
3.4 SUBJECT  IDENTIFICATION  ................................ ................................ ................................ ................................ ....... 10 
3.5 STUDY MATERIALS  AND  LABELING  ................................ ................................ ................................ .............  10 
3.6 STUDY  DURATION  ................................ ................................ ................................ ................................ ................  12 
3.7 STUDY  TERMINATION /SUBJECT  DISCONTINUATION  ................................ ................................ .............  12 
3.7.2  Subject  Discontinuation  ................................ ................................ ................................ ....... 13 
3.8 MATERIAL  ACCOUNTABILITY  ................................ ................................ ................................ ........................  13 
3.9 RANDOMIZATION  AND  BLINDING  ................................ ................................ ................................ ..................  14 
3.10 SOURCE  DATA  ................................ ................................ ................................ ................................ .....................  14 
3.11 PROTOCOL  MODIFICATIONS  ................................ ................................ ................................ ........................  14 
3.11.1  Protocol  Amendments  ................................ ................................ ................................ ........  14 
3.11.2  Protocol  Deviations  ................................ ................................ ................................ ............  15 
4. SUBJECT  SELECTION  ................................ ................................ ................................ ................................ .............  15 
4.1 SUBJECT  INCLUSION  CRITERIA  ................................ ................................ ................................ ......................  15 
4.2 SUBJECT  EXCLUSION  CRITERIA  ................................ ................................ ................................ ....................  16 
4.3 SUBJECT  INFORMED  CONSENT  ................................ ................................ ................................ .......................  16 
4.4 SUBJECT AUTHORIZATION FOR USE AND DISCLOSURE OF PROTECTED HEALTH  
INFORMATION  ................................ ................................ ................................ ................................ ...............................  17 
4.4.1 Subject  Revocation  of Authorization  to Use/Disclose  Protected  Health  Information  ..........  17 
5. TREATMENT  OF SUBJECTS  ................................ ................................ ................................ ................................ .. 18 
5.1 SCHEDULE  OF TREATMENTS  ................................ ................................ ................................ ...........................  18 
5.1.1 Subject  Screening  ................................ ................................ ................................ .................  18 
5.1.2 Initial  Visit  ................................ ................................ ................................ ...........................  18 
Page 5 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
 5.1.3 Follow  Up Visits  ................................ ................................ ................................ ..................  19 
5.1.4 Final  Study  Visit  ................................ ................................ ................................ ..................  19 
5.1.5 Subject Instructions for Interim between 6 -Week  Follow -Up Visits  ................................ .. 20 
5.2 Study  Procedures  ................................ ................................ ................................ ..................  20 
6. SUBJECT  COMPLIANCE  ................................ ................................ ................................ ................................ ........  24 
7. ASSESSMENT  OF EFFICACY  ................................ ................................ ................................ ................................  24 
8. ASSESSMENT  OF SAFETY  ................................ ................................ ................................ ................................ .............  25 
8.1 SAFETY  PARAMETERS  ................................ ................................ ................................ ................................ ........  25 
8.2 ADVERSE  EVENTS  ................................ ................................ ................................ ................................ ................  25 
9. STATISTICS  ................................ ................................ ................................ ................................ ................................  26 
9.1 STATISTICAL  METHODS  ................................ ................................ ................................ ................................ .... 26 
9.1.1 Analysis of Baseline and  Demographic  Characteristics  ................................ ......................  26 
9.1.2 Analysis of Primary  Endpoint  ................................ ................................ ..............................  27 
9.1.3 Analysis of Secondary  endpoints  ................................ ................................ .........................  27 
9.2 SAMPLE  SIZE JUSTIFICATION  ................................ ................................ ................................ .........................  27 
9.3 INTERIM ANALYSES AND CRITERIA FOR THE TERMINATION OF  THE  STUDY  ..............................  27 
10. MONITORING  ................................ ................................ ................................ ................................ .........................  28 
11. QUALITY CONTROL AND  QUALITY  ASSURANCE  ................................ ................................ ..........................  29 
12. ETHICS  ................................ ................................ ................................ ................................ ................................ ...... 30 
13. DATA HANDLING AND  RECORD  KEEPING  ................................ ................................ ................................ .. 30 
13.1 STUDY  PERSONNEL  ................................ ................................ ................................ ................................ ...................  30 
13.2 PRE-STUDY  DOCUMENTATION  REQUIREMENTS  ................................ ................................ ........................  30 
13.3 COMPLETION AND RETURN OF CASE  REPORT  FORMS  ................................ ................................ ...... 31 
13.4 INTERIM  REPORT  ................................ ................................ ................................ ................................ ..............  31 
13.5 FINAL REPORT  ................................ ................................ ................................ ................................ ............................  31 
13.6 RECORDS , REPORTS AND  RETENTION  REQUIREMENTS  ................................ ................................ .... 31 
Page 6 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
 1. Background  Information  
 
1.1 Name, Description and Intended Use of the Product for  Investigation  
 
Orthodontic aligners have been commercially available since 1998 with the introduction of 
Invisalign® Aligners that are an aesthetic alternative for orthodontic treatment. 3M Oral Care 
Solutions Division plans to expand the orthodontic aesthetic solutions portfolio by  offering 
customized 3M Clear Aligners for orthodontic treatment.  
 
The 3M™ Clear Aligner System is a series of clear lightweight plastic appliances (aligners) 
indicated for the treatment of tooth malocclusions in patients with permanent dentition (i.e. all  
second molars). By utilizing a series of incremental tooth movements, (torque, tipping, rotation, 
bodily movements such as intrusion and extrusion) the 3M Clear Aligners sequentially re - 
position teeth by way of continuous gentle force.  
 
The 3M Clear Alig ner System may include attachments and/or buttons, which offer a solution 
for patients, who want an aesthetic treatment with a set of removable clear aligners that correct 
tooth malocclusions without the use of conventional wire and bracket orthodontic tec hnology.  
 
1.2 Risk/Benefit  Summary  
 
1.2.1 Risks  
 
Listed below are the potential and known risks with wearing the 3M Clear Aligners:  
 
• Gastrointestinal tract obstruction resulting from aligner fragments due to  aligner 
breakage, attachment and button  debond.  
• Aspiration of 3M Clear Aligner fragments resulting from breakage, attachment, 
button  debond.  
• Aspiration of attachment or buttons resulting from breakage or bond  failure.  
• Choking due to 3M Clear Aligner fragments resulting from  breakage.  
• Choking due to atta chment or buttons resulting from breakage or bond  failure.  
• Gingival tissue and teeth may become sore and tender after initial  aligner 
placement and when placing each sequential 3M Clear  Aligner.  
• Speech may be affected when initially beginning treatment but should  be 
minimized in 2 weeks after beginning aligner  therapy.  
• Gums, cheeks, and lips may be abraded or irritated by the 3M Clear  Aligners, 
attachments or  buttons  
• Swollen and inflamed gums or tongue while wearing the 3M Clear  Aligners.  
• Enamel damage due to hard debris in aligner or due to removal of tight aligner.  
• Staining of teeth due to poor hygiene, food debris in 3M Clear Aligner, or 
consumption of sugary liquids, or beverages that may cause stains on teeth, i.e. 
coffee,  wine. 
Page 7 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
• Caries, decalcification periodontal  disease and permanent stains may occur if 
consistent and proper oral hygiene such as brushing and flossing are not 
performed as  recommended.  
• Decalcification, and periodontal disease caused by eating an d/or drinking  sugary 
foods and beverages while wearing the 3M Clear  Aligner.  
• Tooth  root damage  due to tooth  movement  too fast or beyond  bond  while  wearing 
the 3M Clear Aligner.  
• The bite may change during the course of treatment resulting in temporary 
discomfort.  
• The bite may require additional adjustments at the end of  treatment.  
• Temporary increase in salivation or dryness of mouth may  occur.  
• Temporal -mandibular joint (TMJ) pain, headaches or ear problems may  occur.  
• Existing dental restorations may become dislodged while removal of tight aligner.  
• Failure to wear the appliance for the prescribed number of hours per day or in  the 
prescribed order and/or not using the 3M Clear Aligner as directed may lengthen 
the treatme nt time and affect the final treatment  outcome.  
• Relapse of teeth after treatment due to the failure of not wearing the  retainers.  
• Attachment debonds which will require rebonding the attachment during  an 
additional  appointment  
• Button  debonds  require  rebonding  the attachment  during  an additional 
appointment  
• Aligners may become  damaged  
• Redness,  swelling  to gums,  lips, due to sensitization  to attachment  composite 
material  
• Toxicity from exposure to uncured attachment  material.  
• Cuts to gingiva,  tongue,  lips due to sharp  or rough  surface  of attachment  material.  
• Respiratory tract irritation due to finishing/polishing dust or removal  of 
attachment remnant  material.  
 
1.2.2 Benefits  
 
The individual receives treatment for correcting tooth malocclusions, while wearing the 3M 
Clear Aligner instead of conventional wire and bracket orthodontic technology. Indirectly, 
subjects may benefit from the additional clinical attention.  
 
1.3 Material  Application  
 
The subjects will undergo a target of up to 18 months of treatment  to align the teeth to the 
planned target. The investigator will receive 6 sets of 3M Clear Aligners per shipment from 3M 
and will then provide each subject with 3 sets at each 6 -week follow up appointment. The 
subject will wear the 3M Clear Aligners for a t least 22 hours per day, with the exception of 
consumption  of meals  and beverages,  with the exception of  water,  which  can be consumed  while 
wearing the aligners. During each 6 -week period between follow up visits, subjects will  wear  
Page 8 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
each set of 3M Clear Aligners for 2 weeks, in the order indicated per the Orthodontists treatment 
plan.  
 
1.4 Good Clinical Practice (GCP) and Regulatory  Requirements  
 
The 3M™ Clear Aligner System is categorized as a Class II, medical device subject to 510(k) 
clearance. The 3M Aligner system has been cleared for use by the Federal Drug Administration. 
This study will be conducted in compliance with this protocol and Good Clinical Practice (GCP).  
 
1.5 Study  Population  
 
The subject population for this study wi ll be male and female subjects ≥ 14 years of age. There 
will be no attempt to enroll equal number of male and female subjects. Subjects who meet the 
inclusion and exclusion criteria will be asked to participate in the study. Up to a total of 180 
subjects m ay be enrolled at up to 12 different clinical research sites, (up to 15 subjects per site).  
 
2. Study Purpose and  Objectives  
 
The purpose of this study is to evaluate the safety and efficacy of the 3M Clear Aligners along 
with the use of attachments and/or bu ttons for the treatment of tooth malocclusions.  
 
2.1 Primary Objective  
 
The primary objective of this study is to evaluate the efficacy of 3M Clear Aligners to correct 
tooth malocclusions with the use of attachments and/or buttons, as determined by the amount of 
teeth movement and overall achievement goals of the treatment plan.  
 
2.2 Secondary Objectives  
 
The secondary objectives of this study are:  
 
• Evaluate  safety.  
• Evaluate individual tooth movements per recommended treatment ranges.  
• Evaluate length of treatment time for different  malocclusions.  
• Evaluate the use of attachments and attachment bond failures when used with  3M 
aligners.  
• Evaluate orthodontist satisfaction with treatment outcome and use of 3M  aligners.  
• Evaluate orthodontist satisfaction with the Treatment Management Portal  Software.  
• Evaluate subject satisfaction with the overall treatment of the 3M Clear Aligners, 
especially  regarding  ease of insertion  and removal,  aesthetics  (discoloration), ease  of 
cleaning and subject compliance while wearing the  aligners.  
• Evaluate number of mid -course corrections or refinements  needed.  
• Evaluate digital scans to predict tooth movement for future product  development.  
Page 9 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
 
3. Study  Design  
 
3.1 Study Type  
 
This is a prospective , multi -center study with a targeted duration of 18 months, to assess the 
safety and efficacy of 3M Clear Aligners, with the use of attachments to correct teeth 
malocclusions.  
 
3.2 Primary and Secondary  Endpoints  
 
3.2.1 Primary  Endpoint  
 
The primary endpoint is the percent of subjects who have achieved correction of tooth 
malocclusions with use of 3M Clear Aligners. The successful correction of the malocclusion 
will be based on the subject’s achievement of the target setup or the treatment plan as judged by 
the O rthodontist.  
 
3.2.2 Secondary  Endpoints  
 
• Safety of 3M Clear Aligners as evaluated by the number of unanticipated adverse  events.  
• Summary  of individual  tooth  movement and  total arch movements,  for example,  tooth 
rotations, tooth intrusions/extrusions, and arch sp ace closures.  
• Summary of treatment times for different tooth  malocclusions  
• Summary of the total number of aligners used, treatment duration and use of  attachments, 
buttons, and bond  failures.  
• Percent satisfaction of orthodontists with treatment  outcome.  
• Percent satisfaction of orthodontist with the 3M Treatment Management Portal  software.  
• Percent satisfaction of subject with overall treatment when using 3M Clear Aligners, such 
as: (aligner  comfort,  pain during  wear,  ease of insertion,  ease of removal,  ease of cleaning 
and satisfaction with  aesthetics).  
• Summary of the number of mid -course corrections or refinements  needed.  
 
3.3 Randomization and  Blinding  
 
This is a single intervention schedule study so no randomization or blinding will occur. Subjects 
who meet the inclusion and exclusion criteria and are willing to sign an informed consent, will 
be asked to participate in the study.  
Page 10 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
 
3.4 Subject  Identification  
 
When a subject is considered eligible for entry into this study, the subj ect will be allocated to a 
subject identification number (subject ID number). The numbers will be sequential.  
 
Subject identification will include the site number followed by the subject number. This number 
will be the unique identifier of the subject on the case report forms and written on each page of 
all other documentation relating to that subject.  
 
A list of enrolled subjects and corresponding subject numbers will be maintained in the 
investigator’s study file.  
 
3.5 Study Materials and  Labeling  
 
3.5.1 Study  Materials  
3M Clear Aligners, attachment template including attachments will be provided by 3M. 
3M Clear Aligners  
The 3M Clear Aligners are clear lightweight plastic appliances (aligners) indicated for the 
treatment of tooth malocclusions. 3M will p rovide 6 stages (12 weeks) of 3M Clear Aligners to 
site per shipment.  
 
3M Attachment Template  
The 3M Attachment Template is a lightweight plastic template used to create attachments on the 
subject's teeth.  
 
3M Attachment Material  
The 3M Attachment Material s are commercially available. The 3M Transbond XT and 
Transbond LV will be made available for Investigator use to create attachments, using the 3M 
Attachment Template.  
 
Buttons  
Investigator may use commercially available buttons for alignment, as indicated per treatment 
plan.  
Page 11 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
A picture of a 3M Clear Aligner is shown below:  
 
• Axxxxxx – 6 digit alpha -numeric order  number  
• U – Upper/Lower arch indicator  
• 01 – indicates the stage number which will change as treatment  progresses  
 
3.5.2 Labeling  
 
3M will label, package and ship the study materials to the clinical site. The aligners and aligner 
packaging used in the study will be labeled with the following minimum information:  
 
• Medical Device  
• Order number – AxxxxxxABC  
• 3M Unitek  Orthodontic Products  
• Study material name or code  designation  
• Identifying  lot 
• Quantity of  contents  
• Include the following information as  appropriate:  
• Necessary caution statements (e.g. specific contraindications, hazards, adverse effects, 
interfering substa nces, devices or drugs, warnings and precautions that need to appear on 
the label for safe product  use) 
• Not for commercial distribution. For clinical use  only.  
• Storage  conditions  
• Expiration  date 

Page 12 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
 
 
 
Material Label Statements  
The 3M Clear Aligners and 3M Attachment Template are available for clinical use and has 
received Federal Drug Administration clearance.  
 
3.6 Study  Duration  
 
The expected  duration of  subject  participation  may be 6 to 24 months,  even  though  the maximum 
targeted duration is 18 months. The duration could be extended due to mid -course corrections or 
refinements, as determined by the Investigator. The subject is expected to attend study visits  at 
6-week intervals for the duration of the study. Study visits may range from a minimum of 7 to 
18 scheduled visits, dependent on the duration indicated per the investigators treatment plan for 
each subject. Additional visits may be scheduled per Investigator  discretion.  
 
3.7 Study Termination/Subject Discontinuation  
 
3.7.1 Study  Termination  
 
3M or the Investigator has the right to discontinue the study at any time for medical and/or 
administrative reasons, after mutual consultation, if possible.  
 
The orthodontist, dentists or study sites have the right to discontinue this study at any time for 
safety and/or administrative reasons. If the study is discontinued prematurely, orthodontists, and 
subjects will be notified and proper documentation of the reas on for discontinuation will be 
prepared. The IRB will be informed promptly and provided the reasons(s) for the termination or 
suspension by 3M.  

Page 13 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
3.7.2 Subject  Discontinuation  
 
The Investigator may discontinue individual subjects from the study at any time. Subjects may 
voluntarily withdraw from the study at any time. The Investigator will provide a written report 
on the appropriate  CRF  describing  the reason  for discontinuance  and the date of discontinuance.  
 
A subject will be discontinued from the study if any of the following occur:  
 
• Subject fails to comply with instructions for wearing the 3M Clear Aligner  as 
indicated per the Investigator treatment plan, for the duration  required.  
• Subject fails to show up at scheduled visits. Attempts will be made to schedule 
subjects and if they are not responsive, they may be  discontinued.  
• Subject elects to terminate participation in the  study.  
• Investigator elects to withdraw the subject (with written justifications  about 
safety, noncompliance or for other safet y reasons).  
• Subject experiences a severe adverse reaction to the 3M Clear  Aligner.  
• Subject requires dental work that cannot wait until the end of the  study.  
 
Subjects who are withdrawn after wearing aligners will not be replaced. If possible, any 
procedures or assessments planned for the subject on withdrawal from the study should be 
performed when intention to withdraw the subject is announced  
 
3.8 Material  Accountability  
 
Accountability and adequate inventory security will be maintained at all times.  
 
• Investigator will maintain materials in a secure storage area, accessible only to  authorized 
site personnel.  
• Investigator will dispense study material only to enrolled  subjects.  
• Investigator will return all used 3M Clear Aligners to 3M after each subject 's 6 week 
follow up visit within 1  week.  
• Investigator will return all unused 3M Aligner System materials to 3M after subjects  have 
completed all follow up visits.  
Page 14 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
The Principal Investigator or an authorized designee shall keep records documenting the receipt, 
use, and return of the 3M aligner system materials, which shall include:  
 
• Date of  receipt  
• Identification of each 3M Clear Aligner; unique aligner identification and lot numbers  
• Date of  use 
• Subject identification  numbers  
• Date on which the 3M Clear Aligners were returned to the  3M 
• Date of return of unused, expired or malfunctioning 3M aligner system materials to  3M 
 
3M will keep records to document shipment of 3M Clear Aligners to the clinical sites and all 
returned 3M Clear Aligne rs. 
 
 
3.9 Randomization and  Blinding  
 
There will not be any randomization or blinding associated with this study, as it is a single 
intervention schedule. Subjects who meet the inclusion and exclusion criteria will be asked to 
participate in the study.  
 
3.10 Source  Data  
 
Source documents are defined as the results of original observations and activities of a clinical 
investigation. Source documents will include, but are not limited to, paper copies of CRFs with 
original data, study progress notes, computer pri ntouts, screening logs, laboratory notebooks,  and 
recorded data from automated instruments. All source documents produced in this study will be 
maintained by the Investigator and made available for inspection by authorized persons. Paper 
CRFs will be the p rimary source documents for the study. All data will be directly recorded on 
the paper CRFs and later transferred to the electronic CRFs.  Documentation may include, but 
are not limited to performance data, qualification criteria and any raw data generated  for the 
study. The original signed informed consent form from each participating subject shall be filed 
in the Regulatory Folder and a copy provided to  subject . 
 
3.11 Protocol  Modifications  
 
3.11.1  Protocol  Amendments  
 
The party initiating an amendment must confirm i t clearly in writing using the 
Amendment/Administrative Revision form. It must be signed and dated by 3M and, in the case 
of a significant amendment, the Investigator. A significant amendment means one that affects 
the safety, rights or welfare of subjects , the scope of the investigation or the scientific quality of 
the study.  
Page 15 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
 
3.11.2  Protocol  Deviations  
 
A deviation is a departure from the protocol that will likely affect the safety, rights or welfare of 
subjects, the scope of the investigation or the scientific quality of the study.  
 
A protocol deviation is only for an individual subject. Protocol deviations are documented on a 
Protocol Deviation Form or appropriate CRF.  
 
Deviations that potentially affect 1) subject safety, rights or welfare, 2) data integrity or 3) 
compromise the statistical analysis of the study require immediate communication to 3M. The 
Investigator must contact the 3M study monitor within 24 hours of occurrence.  
 
A Protocol Deviation Form must be complete d by the Investigator and include the type of 
deviation and a description of the circumstances surrounding the deviation. A copy is sent to the 
3M study monitor within 24 hours of identifying the occurrence.  
 
Deviations which are made to protect the life o r physical well -being of a subject in an 
emergency must be reported to the IRB within 5 working days after 3M learns of the 
occurrence.  
 
Any finding that is considered to have a significant impact on the study objectives or integrity of 
the study as assess ed by the Principal Investigator will be reported to the 3M as soon as it is 
possible to do so.  
 
3M Clear Aligners worn less than 22 hours per day will not be considered a protocol deviation, 
but will be recorded as non -compliance on the CRF.  
 
4. Subject  Selection  
 
4.1 Subject Inclusion  Criteria  
Subjects to whom all of these conditions apply will be eligible to participate in this study:  
 
1. Subject is at least 14 years of  age. 
2. Subject is willing and able to give informed  consent.  
3. Subject is willing to be digitally scanned at each 6 -week visit, including after  application 
of attachments.  
4. Subject has a need for single or double arch orthodontic treatment with a target  duration 
of 18 months or  less. 
5. Subject has good oral hygiene defined by the  orthodontist.  
6. Subject has only permanent  dentition.  
Page 16 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
4.2 Subject Exclusion  Criteria  
 
Subjects to whom any of these conditions apply will be excluded from participating in this study:  
 
1. Subject has skeletal discrepancies requiring  surgery  
2. Subject is undergoing active dental  work  
3. Subject has severe open bite > 2 mm 
4. Subject has severe overjet > 4  mm 
5. Subject has deep bite > 3  mm 
6. Subject has over crowding per arch > 4  mm 
7. Subject has dental prostheses/implants that will interfere with projected teeth  movem ent 
8. Subject is taking systemic steroid  medication  
9. Subject is taking Biphosphonates or any other medication for treatment of  osteoporosis  
 
4.3 Subject Informed  Consent  
 
The Investigator must ensure that written informed consent to participate in the investigati on is 
obtained before including any individual as a subject in the investigation. The Investigator must 
provide the prospective subject or the representative sufficient opportunity to consider whether or 
not to participate, and minimize the possibility of coercion or undue influence. The process is 
designed to 1) give the subject all the information that they need, 2) ensure that the subject 
understands the information and 3) give the subject a chance to consider study participation. The 
process should perm it the subject to ask questions and exchange information freely.  
 
Specifically, the Investigator will explain to each subject all elements of informed consent as 
specified in 21 CFR 50.25 (Appendix 14). After the explanation, the subject or representative 
will voluntarily sign and date the consent form if they wish to participate in the study. A copy of 
the consent form must be provided to the subject. A signed and dated copy of the consent form 
must be maintained in the Investigator study documentation file at all times.  The consent process 
and study participation, with date, must be documented in the patient  record/chart.  
 
For children under 18 years of age:  
Prior to entering the study, the Investigator or qualified designee will explain to each legal 
parental custodian the nature of the study, its purpose, procedures, expected duration, and the 
benefits and risks involved in study participation. The study sho uld also be explained to all 
subjects regardless of age to the fullest extent possible. Each legal parental custodian will be 
given an information and consent document and ample opportunity to ask questions. The legal 
parental custodian(s) will be informed  of the subject’s right to withdraw from the study at any 
time without prejudice. Subjects should also be given the opportunity to ask questions and be 
informed of their right to withdraw from the study. After this explanation and before any study - 
specifi c procedures have been performed, subjects may voluntarily assent to enroll in the study 
(the age of assent will be determined by the IRB, consistent with local laws, generally 7 years 
of age) and their legal parental custodian(s) may voluntarily sign and  date an informed consent 
statement, thereby giving permission for their charges to enter the study. Prior to participation in  
Page 17 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
the study, the subject and their legal parental custodian(s) will receive a copy of the signed and 
dated written i nformed consent and assent forms and any other written information provided to 
the subject.  
 
Written assent is generally not required of subjects <7 years of age due to maturation levels, 
depending on IRB policy and local laws. Their legal parental custodi an(s) are responsible for 
evaluating the proposed study and providing written consent (permission) for their charges to 
enter the study. It is the Investigator’s responsibility to ensure that the individual signing the 
informed consent document is the lega l custodian for the subject. Impartial witness and/or 
Investigator  signature  and date will be added  to the consent  and assent  documents  if required  by 
IRB policy.  
 
Written informed consent or assent for each subject must be obtained before any study relate d 
procedures are performed.  
 
4.4 Subject Authorization for Use and Disclosure of Protected Health  Information  
 
The Investigator must ensure that written authorization for use and disclosure of protected health 
information is obtained before including any indiv idual as a subject in the investigation.  
 
Specifically, the Investigator is to explain to each subject all elements of authorization as 
specified in 45 CFR 164.508. After the explanation, the subject or representative must 
voluntarily sign and date the authorization form if they wish to participate in the study. A copy 
of the authorization form must be provided to the subject. A signed and dated copy of the 
authorization form must be maintained in the Investigator study documentation file at all times 
and may be placed in the patient’s medical record.  
 
An authorization form may be combined with a consent form (i.e. compound authorization) if 
required by the IRB. All required elements for both informed consent and authorization must be 
included in a compou nd authorization.  
 
4.4.1 Subject  Revocation  of Authorization  to Use/Disclose  Protected  Health  Information  
 
In order  to implement  a valid  revocation  of authorization,  the subject  or their representative  must 
make the request in writing to the Western Institutional Review Board. The revocation cannot 
stop the use or disclosure of information that has been collected prior to the revocation, is needed 
to ensure complete and accurate study results, is required by law or government regulation (e.g. 
reporting adverse events, etc.). Revocation of an authorization may not be used to withhold 
normal medical care from the subject, but may make the subject ineligible to receive the study 
treatment or  care.  
Page 18 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
5. Treatment of  Subjects  
 
5.1 Schedule of Treatments  
 
The 3M Aligner System includes a series of aligners that offer a solution for patients who want 
an aesthetic treatment with a set of removable aligners to correct tooth malocclusions without the 
use of conventional wire and bracket orthodontic technology. The 3M Clear Aligners are being 
studied in a manner consistent with their intended use.  
 
The Principal Investigators will treat subjects requiring correction of tooth malocclusions using 
the 3M Clear Al igners with attachments and/or buttons as necessary for additional force applied 
to teeth or to help with tooth movement.  
 
5.1.1 Subject  Screening  
Investigator will screen subjects for treatment of tooth malocclusion, as well as for study 
inclusion and exclusion  criteria. If subject qualifies for the clinical study per the Investigator's 
examination, they will be provided with informed consent, per Good Clinical Practices. After 
subjects have signed the Informed Consent document, the investigator will determine w hether 
subject's teeth should be cleaned by a hygienist before being scanned.  
 
5.1.2 Initial  Visit  
• Determine subject  eligibility.  
• Consent eligible  subjects.  
• Investigator conduct initial examination and develop treatment  plan.  
• Generate initial digital scan of subject's  teeth.  
• Generate Pano -Ceph scan of subject's  teeth.  
• Generate Photos of subject’s  teeth.  
• For 3M™ True Definition Scanner upload the digital scan to 3M Study Lab  50005.  
• For Itero  users,  retrieve  the STL files from  MyAligntech.com  using  OrthoCad  export  and 
save the STL scan files to local  computer.  
• For other  scanner  users,  download  the STL file to a local  computer  and upload  the scan 
into the Treatment Management Portal  website.  
• Submit Treatment  Management  Portal  order,  with attached  scan files,  photographs  and 
Pan-Ceph  scans.  
• Initial study documentation for each subject needs to be completed as  follows:  
▪ Submit treatment order plan for each subject within 1 week of initial  visit.  
▪ Upon receipt of final Target Set -up plan, approve or decline within 3  days.  
▪ Upon receipt of final Staging Set -up plan, approve or decline within 3  days.  
 
Upon receipt of subject digital scan, Pano -Ceph scan, photos and Aligner specifications, 3M will 
generate (6 stages) 12 weeks of 3M Clear Aligners for subj ect. 3M Clear Aligners will be 
shipped to clinical site prior to subject's next scheduled 6 -week follow up visit.  
Page 19 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
If timelines for treatment order plan and approvals for Target and Staging set -ups are not 
followed, this may impact 3M's abili ty to timely provide 3M Clear Aligners for subject follow - 
up visits.  
 
5.1.3 Follow Up  Visits  
• Investigator will conduct follow up examination  
• Generate  digital  scan of subject's  teeth  after application  of attachments  during  first follow 
up visit and at each subsequent follow up  visit.  
• Investigator will assess 3M Clear Aligners for  defects.  
• Investigator will assess fit of 3M Clear  Aligners.  
• Investigator will assess seating and removal of 3M Clear  Aligners.  
• Investigator will inspect previously worn 3M Clear Aligners for damage and  aesthetics.  
• Investigator will assess subject’s teeth for missing attachments and/or  buttons.  
• Investigator will assess treatment  progress.  
• Investigator will assess soft tissue  condition.  
• Investigator will assess decision for mi d-course correction or  refinement.  
• Investigator will provide subject with next 3 stages of 3M Clear  Aligners.  
(Subjects will receive a total of three sets of 3M Clear Aligners (3 stages) at each 6 -week 
visit.)  
• Collect used 3M Clear Aligners from subject.  
• Schedule subject's next 6 -week study  appointment.  
• For 3M™ True Definition Scanner upload the digital scan to 3M Study Lab  50005.  
• When  using  Itero,  Trios  or other  scanners,  retrieve  the STL files and save the STL scan 
files to local computer. Scan will be provided to  3M. 
• If applicable, submit new order for mid -course correction or  refinement.  
• Complete study documentation for each subject within 1 week of each  visit.  
 
5.1.4 Final Study  Visit  
• Investigator conducts final study  examination.  
• Generate digital scan of s ubject's  teeth.  
• Investigator will assess treatment  progress.  
• Investigator will assess soft tissue  condition.  
• Retainers will be provided to subject 2 – 3 weeks after final clinical study  visit.  
• Instruct subject to wear last set of 3M Clear Aligners until retainers are  available.  
• For 3M™ True Definition Scanner upload the digital scan to 3M Study Lab  50005.  
• When  using  Itero,  Trios  or other  scanners,  retrieve  the STL files and save the STL scan 
files to local computer. Scan will be provided to  3M. 
• Log into Treatment Management Portal, go to the patient list and select the  subject 
number.  
Page 20 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
• Select the Treatment Complete icon. This will inform manufacturing to use the final 
stage set -up model to manufacture three sets of  retainers.  
• Comple te study documentation for each subject within 1 week of each  visit.  
 
5.1.5 Subject Instructions for Interim between 6 -Week Follow -Up Visits  
Subject will wear the 3M Clear Aligners for at least 22 hours per day with the exception of meals 
and beverages other than water.  
• Subjects wear each of the (3) 3M Clear Aligner sets for two weeks, during the  six-week 
period between study  visits.  
 
3M Clear Aligners Sets 1 - 3 
 
3M Clear Aligner Sets Duration of Wear for Each Set  
(6 weeks total)  
Set # 1  Upper and Lower  
3M Clear  Aligners  2 
Set # 2  Upper and Lower  
3M Clear  Aligners  2 
Set # 3  Upper and Lower  
3M Clear  Aligners  2 
 
• Subjects will receive 3 Stages of 3M Clear Aligners at every 6 week follow -up visit.  
 
5.2 Study  Procedures  
 
Instructions will be provided for the following procedures:  
 
• Digital  Scanning  
• Submitting a 3M Clear Aligner order through 3M Treatment Management  Portal.  
• Target Set -Up and Staged Set -up Review and  Approval  
• Treatment with 3M Clear  Aligners  
• Instructions for Placing  Attachments  
• Patient Use and Care  Instructions  
 
5.2.1 Digital Scanning  criteria:  
 
• Subject will brush teeth prior to digital  scan.  
• Scan incisal edges and marginal  ridges.  
• Scan complete occlusal surfaces (no holes  present).  
• Scan inter -proximal  spaces.  
• Scan with cle ar gingival margin and 3 -5 mm of lingual and buccal  gingiva.  
• Scan palatal  rugae.  
Page 
21
 
of
 
31
 
Status:
 
Release
 
Version:
 
4
 
Issue Date: 4/19/2017 9:53:31
 
AM
 
Health Care 
3M Center
 
St. Paul, MN 55144
-
1000
 
3M 
Confidential
 
Document Name: CLIN
-
PROT
-
ICH
-
US
-
05
-
300635
 
Clinical and Non
-
Clinical: CLIN
-
INDEX
-
3M
-
SPON
-
US
-
05
-
013821, Clinical and Non
-
Clinical: CLIN
-
INDEX
-
 
3M
-
SPON
-
US
-
11
-
050005
 
 
 
 
•
 
Scan left and right bite scans to include 3 to 5 teeth in each scan, to ensure proper 
occlusion.
 
•
 
Scan the terminal
 
molars.
 
•
 
Do not scan anterior
 
bite.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-
 
 
 
 
 
 
 
 
 
 
 
–
-
 
 
 
 

Page 
22
 
of
 
31
 
Status:
 
Release
 
Version:
 
4
 
Issue Date: 4/19/2017 9:53:31
 
AM
 
Health Care 
3M Center
 
St. Paul, MN 55144
-
1000
 
3M 
Confidential
 
Document Name: CLIN
-
PROT
-
ICH
-
US
-
05
-
300635
 
Clinical and Non
-
Clinical: CLIN
-
INDEX
-
3M
-
SPON
-
US
-
05
-
013821, Clinical and Non
-
Clinical: CLIN
-
INDEX
-
 
3M
-
SPON
-
US
-
11
-
050005
 
 
 
 
 
 
 
 
 
 
-
–
 
 
 
 
–
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2.4
 
Attachments
 
Based upon the investigator treatment plan, composite based attachments may be placed on the 
subject's teeth by the 
investigator using the 3M Attachment Template. Attachments are used to 
assist the 3M Clear Aligners in certain tooth movements or to engage the 3M Clear Aligners to 
directly apply pressure to certain teeth depending on the tooth size, shape and angulation.
 

Page 23 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
 
Investigators may also place buttons they currently use in practice on the subjects teeth to assist 
with creating tooth movements and correcting occlusion in conjunction with attachments.  
Investigators may use buttons with elastics to assi st in creating tooth movements such as 
rotation, intrusion, extrusion, translation. Investigators will bond the buttons onto the subjects’ 
teeth according to the manufacturer’s instructions. The investigator may modify the 3M Clear 
Aligner as needed, so th at the 3M Clear Aligners fit around the buttons on the teeth.  
 
Instructions for placing 3M attachments using the 3M Attachment Template can be found in the 
Aligner Attachment instructions for use. Instructions will cover the following:  
 
• Tooth preparation  
• Acid  Etching  
• Priming Teeth  
• Bond the attachments and light cure  
• Inspect the 3M Clear Aligners for any  defects.  
• Seat the 3M Clear Aligners to assess fit and adjust as  needed.  
• Assess the removal of the 3M Clear Aligners and adjust as  needed.  
 
For bonding buttons, follow the manufacturer instructions for use.  
 
• Bond the buttons and modify the 3M Clear Aligners as needed to fit around the  buttons.  
• Inspect the 3M Clear Aligners for any  defects.  
• Seat the 3M Clear Aligners to assess fit and adjust as  needed. 
• Assess the removal of the 3M Clear Aligners and adjust as  needed.  
 
If the 3M Clear Aligners are not able to be seated and/or do not fit, contact 3M clinical 
study monitor.  
5.2.5 Treatment with 3M Clear Aligners 
After placement of the 3M Clear  Aligners:  
• Instruct subject on how to insert and remove the 3M Clear Aligners. Make sure  subject  
is able to insert and remove 3M Clear Aligners before they leave the office. Investigator 
may provide auxiliaries to help subject with comfort while wearing 3M Clear Alig ners 
and help with removal of the 3M Clear Aligners.  
• Review and discuss the Patient Care and Use Instruction Sheet with  subject.  
• Allow each subject adequate time to ask  questions.  
Page 24 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
• Provide subject with a 3M Clear Aligner case box.  
• Inform the subject to return all 3M Clear Aligners in the original packaging along with 
the white  box. 
• In the event that a 3M Clear Aligner is lost or damaged, instruct subject to contact the 
office  immediately.  
• If a 3M Clear  Aligner  is lost  or breaks  within  less than 7 days,  instruct  subject  to begin 
wearing the previous set of 3M Clear  Aligners.  
• If a 3M Clear Aligner is lost or breaks after 7 days or more, instruct subject to begin 
wearing the next set of 3M Clear Aligners.  
• Site will return all  used and damaged 3M Clear Aligners to study  3M. 
• Use shipping labels provided by  3M. 
• Return  3M Clear  Aligners in  packaging  provided  and complete  required  packaging 
documentation.  
 
If a 3M Clear Aligner is broken or lost, site should contact 3M clinical study monitor for 
replacement.  
 
5.2.6 Mid-Course Correction or  Refinement  
 
In the event of a mid -course treatment correction or refinement, the following procedures should 
be followed:  
 
• Generate digital scan of subject's  teeth.  
• Go to the Ordering Page in Treatment Management Portal and select option 6 to indicate 
that further treatment stages are  cancelled.  
• Submit new Treatment Management Portal  order.  
• After notification, review and approve both new target and stage  set-ups. 
• Corrected trea tment will continue with 3M Clear Aligners identified as Tray #  1. 
 
6. Subject  Compliance  
 
Routine office visits will be used to encourage subject compliance to study protocol. A 3M 
representative will monitor sites to oversee study documentation and complian ce with study 
protocol.  
 
7. Assessment of  Efficacy  
 
Efficacy of the 3M Clear Aligners for each subject will be based on the assessment by the 
investigator that teeth correction is progressing as expected at each orthodontic visit, and that the 
subject's teeth have reached the final target set -up by the end of treatment.  
Page 25 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
 
8. Assessment of  Safety  
 
8.1 Safety  Parameters  
 
The primary measures of safety will be evaluated by the incidence of adverse events reported 
during the study.  
8.2 Adverse  Events  
 
The Investigator is responsible for identifying adverse events that occur to each subject 
throughout the study and follow -up period. An adverse event can occur at any time during the 
conduct of the study, in any phase of the study or after the study is completed. An adverse event 
can be identified by the Investigator or reported by the subject.  
 
Note: The Federal Privacy Rule (HIPAA) specifically permits the use and disclosure of protected 
health information “without written authorization of  the individual” when used for public health 
activities such as reporting adverse events, tracking FDA -related products, enabling recalls, 
repairs, replacements, lookbacks, or conducting post -market surveillance [45 CFR 164.512].  
This use and disclosure is  subject to the minimum necessary standard, i.e. “the minimum 
necessary to accomplish the intended use, disclosure, or request” [45 CFR 164.502(b)(1)].  
 
Definitions  
 
● Adverse event  (AE) means any undesirable clinical occurrence in a subject whether  or 
not it is considered to be device or drug  related.  
 
● Device -related adverse event (adverse device effect)  is an AE considered by the 
Investigator  to have  a reasonable  likelihood  of being associated  with the treatment 
device.  
 
● Serious adverse device effect  is a device effect that has a serious adverse effect on health 
or safety causing hospitalization or prolonged hospitalization, or is life threatening or 
causes  death.  
 
● Adverse drug experience  is an AE that is considered by the Investigator to have a 
reasonabl e likelihood of being associated with the treatment  drug.  
 
● Serious adverse drug experience  is an adverse drug experience that is fatal or life - 
threatening,  requires  inpatient hospitalization  or prolongation  of existing  hospitalization, 
a persistent or sig nificant disability/incapacity, or results in a congenital anomaly/birth 
defect.  
 
● An Unanticipated Adverse Device Effect  (UADE) means any serious adverse effect on 
health or safety or any life -threatening problem or death caused by or associated with  a 
Page 26 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
device, if that effect, problem or death was not previously identified in nature, severity or 
degree of incidence in the Protocol or application (including a supplementary plan or 
application), or any other unanticipated serious problem associated with a device that 
relates to the rights, safety, or welfare of subjects.  
 
All adverse events will be followed until they are resolved or for 30 days after the subject’s 
participation in the study ends.  
 
Recording and Reporting  
 
The Inve stigator records each material -related adverse event on an Adverse Device Effect 
Record . Documentation includes the description, severity, seriousness, date of onset and 
resolution, relationship to the treatment material, action taken and outcome.  
 
The Investigator must promptly report an adverse device effect to the 3M study monitor. If the 
adverse device effect is also considered by the Investigator to be serious and/or unanticipated, 
the Investigator must report it to the IRB as soon as possible and w ithin IRB requirements.  
 
A serious AE involving a non -3M commercialized product is reported to the 3M study monitor 
and IRB of record.  
 
If a subject has no adverse device effect during the study, the absence of such must be recorded 
on the CRF.  
 
9. Statistics  
 
The primary efficacy dataset will include all subjects enrolled who have worn at least one set or 
first stage of 3M Clear Aligners in the study. The primary dataset will be referred to as the full 
analysis set or FAS.  
 
A secondary efficacy dataset will be defined as the per protocol or PP dataset. This PP dataset 
will exclude subjects with major protocol deviations that will affect efficacy assessment of the 
3M Clear Aligners. The major deviations that will lead to exclusion from the PP dataset will  be 
fully documented and justified in the Statistical Analysis Plan (SAP) and/or pre -lock data 
meeting minutes. Two major protocol deviations that will lead to PP exclusion include 
significant non -compliance with aligner wear and not completing treatment d ue to non - 
treatment -related reasons (e.g. unexpectedly moving out of state). In general, a subject’s failure 
to complete treatment due to strongly anchored teeth will be considered a treatment failure.  
 
9.1 Statistical  Methods  
 
9.1.1 Analysis of Baseline and Demogr aphic  Characteristics  
Page 27 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
Subject demographics (age, gender) will be summarized for all enrolled subjects and for those 
considered evaluable for the primary endpoint. Individual subject malocclusions diagnosed at 
baseline or study enrollment wil l be summarized also.  
 
9.1.2 Analysis of Primary  Endpoint  
 
The primary endpoint is the proportion of subjects achieving treatment success or attainment of 
teeth movements targets of the final set -up. It is possible for the final set -up to be modified mid - 
treatm ent or to be refined at the end of treatment, and thus success of the aligner with be based 
on the last or most relevant final set -up. Primary endpoint will be ascertained at the end of active 
3M Clear Aligner wear (before retainer use).  Subjects missing their primary endpoint 
assessment (e.g., subjects lost to follow -up) will be assumed to be treatment failures. The two - 
sided 95% confidence interval of this proportion will be computed using the Wilson score 
method. Documentation of subjects excluded from  either the FAS or PP datasets for the 
computation of success rate will be justified and documented prior to  datalock.  
 
9.1.3 Analysis of Secondary  endpoints  
 
In general, the reported summary statistics for continuous measures will include number, mean, 
standard deviation, median and range. Reported summary statistics for categorical measures will 
include number and frequency.  
 
Summaries of the overall percent completion or accuracy per subject will be summarized overall 
and for those categorized under tr eatment success or failure. Percent completion or percent 
accuracy will involve comparison of the final tooth positions relative to the planned or targeted 
positions against pre -treatment or baseline positions.  
 
In addition, individual teeth movement and t he malocclusions resolved in this study will be 
summarized as appropriate.  
 
The secondary endpoints of treatment compliance, percent comfort and percent satisfaction will 
be summarized for various performance parameters.  
 
Furthermore, summaries of attachment use, button use, and possible bond failures will be 
presented. In addition, occurrence of mid-course corrections and refinements will be 
summarized.  
 
9.2 Sample Size  Justification  
 
The sample size for the study will be up t o 180 subjects. The sample size was based on historical 
subject compliance and understanding of alignment procedures.  
 
9.3 Interim analyses and Criteria for the Termination of the  Study  
Page 28 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
At least one interim case study summary analysis may be conducted to examine the data 
regarding efficacy, safety and protocol deviations. A decision to stop the study may follow the 
interim summary analysis based on clinical results.  
 
Given that no formal statistical testing will occur in this study, no allowan ce for alpha spending 
will be needed with any interim analysis.  
 
10. Monitoring  
 
3M, as sponsor of this study, is responsible for ensuring the proper conduct of the study with 
regard to protocol adherence and validity of the data recorded on the CRFs. 3M has t herefore 
assigned a study monitor to this study. The monitor will be responsible for securing the 
compliance of the Principal Investigators to the signed agreement, the study Protocol and all 
applicable FDA regulations, guidelines and standards. The specif ic plans for monitoring will be 
detailed in the Monitoring Plan.  
 
The assigned study monitor will conduct regular monitoring visits to the study site for which 
he/she is responsible. The Principal Investigator will allow the study monitor to inspect all Ca se 
Report Forms and the subject’s clinic records and/or original medical records at these visits. 
These visits are for the purpose of verifying adherence to the Protocol and the completeness and 
accuracy of the data being entered on the Case Report Forms. The Investigator must make 
available the following for inspection and copying, in addition to any other documents deemed 
necessary for the integrity of the study data:  
 
• Informed consent forms and HIPAA forms  
• Protocol amendments, IRB/EC  approval  
• Protocol  deviations  
• Facilities at the study  site 
• Accounting of all 3M Clear  Aligners  
• Adverse events/adverse device effects that have been documented and reported 
The progress of the study will be monitored  by: 
• Periodic on -site review  
• Telephone  communications  
• Review of CRFs and source documents (e.g. patient hospital records, clinical charts, 
progress/doctor’s notes, lab test results, x -rays,  etc.) 
 
 
Note: The Federal Privacy rule (HIPAA) specifically permits the use and disclosure of protected 
health information “to a person subject to the jurisdiction of the Food and Drug Administration 
(FDA) [e.g. study sponsor] with respect to an FDA -related product or activity for which that  
Page 29 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
person has responsibility, for the purpose of activit ies related to the quality, safety, or 
effectiveness of such FDA -regulated product or activity” [45 CFR 164.512(b)(1)(iii)].  
 
11. Quality Control and Quality  Assurance  
 
3M is responsible for implementing and maintaining quality assurance and quality control 
systems through written standard operating procedures (SOPs) to ensure that this study is 
conducted and data are generated, documented and reported in compliance with the protocol, 
GCP and regulations cited in Section 1.5 of this protocol. Study mo nitoring is carried out to 
accomplish this.  
Page 30 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
12. Ethics  
 
This study will be conducted in accordance with the principles that have their origin in the 
Declaration of Helsinki, 21 CFR 50 (Informed Consent) and 56 (IRBs).  
 
The study will start only after approval of the protocol and consent form by the IRB. The 
approval letter or notice must contain the IRB name and identification number, meeting date, and 
sufficient information to identify the protocol and informed consent by name and number that 
were reviewed. 3M, prior to study initiation, must receive a copy of the IRB approval letter.  
 
A description of this clinical trial will be available on http://www.Clinical  Trials.gov, as required 
by U.S. Law. This Web site will not include information that can identify individual subjects. At 
most, the Web site will include a summary of the results. Subjects may search this Web site at 
any time.  
 
Confidentiality of subject data will be maintained at all times. Subject anonymity will be 
maintained and all doc umentation relating to a subject will be kept in a secure location.  
 
13. Data Handling and Record Keeping  
 
13.1 Study  Personnel  
 
Prior to study initiation, the Investigator must provide 3M with a signed investigator 
agreement (Statement of Investigator). The agreement contains pertinent investigator 
information (e.g. qualifications, experience, etc.) as well as the Investigator’s 
commitment to conduct the study according to the protocol and all applicable state and 
federal regulations.  
 
13.2 Pre-Study Documentation  Requirements  
 
Prior to study initiation, the Investigator must provide 3M with the following documents:  
 
• Signed protocol including any amendments in place prior to study  initiation  
• Curriculum vitae for the Investigator and any  co-investigators  
• IRB approved waiver of consent and/or  authorization  
• IRB approved consent  form.  
• Authorization  form  
• IRB study approval  letter  
• IRB name, location and  chairperson  
• Financial Disclosure documents per 21 CFR  54 
• Signed research agreement  
Page 31 of 31 
Status:  Release  
Version:  4 
Issue Date: 4/19/2017 9:53:31  AM Health Care 
3M Center  
St. Paul, MN 55144 -1000  
3M Confidential  
Document Name: CLIN -PROT -ICH-US-05-300635  
Clinical and Non -Clinical: CLIN -INDEX -3M-SPON -US-05-013821, Clinical and Non -Clinical: CLIN -INDEX - 
3M-SPON -US-11-050005   
  
13.3 Completion and Return of Case Report  Forms  
 
3M intends to use electronic data capture (eDC) software for this study. Sites will be trained on 
the eDC software prior to study enrollment. Each site will be provided with a manual, including 
instructions on how to complete the CRFs and how to make CRF corrections. Data may be 
recorded onto data collection sheets prior to data entry or may be entered directly into the eDC 
system. Once the forms are completed, the monitor will review the CRFs to a ssure accuracy and 
completeness. The Investigator must review and sign the CRFs for each subject in a timely 
fashion following completion.  
 
13.4 Interim  Report  
 
Interim summaries of individual case reports may be written during the course of this study.  
 
13.5 Final  Report  
 
3M will prepare and submit a Sponsor Final Report to all reviewing IRBs within 6 months after 
study completion or termination [see 21 CFR 812.150 (b)(7)].  
 
 
13.6 Records, Reports and Retention  Requirements  
 
The Investigator will maintain study records for a minimum of 2 years following 
completion of the study. Records that must be maintained by the Investigator include, 
but are not restricted to:  
 
● Signed study protocol, amendments,  deviations  
● IRB approval of protocol, consent form, authori zation form* waiver of consent and/or 
authorization and amendments to any of these  documents  
● Applications to the  IRB 
● Signed consent and authorization  forms  
● Case report  forms  
● Adverse event  reports  
● Correspondence relating to the  study  
● Sponsor Final  Report  